Cargando…
Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade
Antibodies targeting the co-inhibitory receptor programmed cell death 1 (PDCD1, best known as PD-1) or its main ligand CD274 (best known as PD-L1) have shown some activity in patients with metastatic triple-negative breast cancer (TNBC), especially in a recent Phase III clinical trial combining PD-L...
Autores principales: | Pilones, Karsten A., Hensler, Michal, Daviaud, Camille, Kraynak, Jeffrey, Fucikova, Jitka, Galluzzi, Lorenzo, Demaria, Sandra, Formenti, Silvia C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583495/ https://www.ncbi.nlm.nih.gov/pubmed/33150045 http://dx.doi.org/10.1080/2162402X.2020.1830524 |
Ejemplares similares
-
LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells
por: Yamazaki, Takahiro, et al.
Publicado: (2021) -
Evaluating the Immunomodulatory Profile and Treatment Efficacy of Whole Lung Low-Dose Radiation Therapy (LDRT) in a Preclinical Model of Severe Viral Pneumonia
por: Dhanota, N., et al.
Publicado: (2021) -
Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade
por: Pilones, Karsten, et al.
Publicado: (2014) -
Radiotherapy induces responsiveness of a resistant mammary carcinoma to PD-1 blockade
por: Diamond, Julie, et al.
Publicado: (2014) -
Mechanisms of synergy of radiotherapy and immunotherapy
por: Pilones, Karsten A, et al.
Publicado: (2015)